Similar articles

• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

  Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Youssef S, et al. Nature. 2002 Nov 7;420(6911):78-84. doi: 10.1038/nature01158. Nature. 2002. PMID: 12422218
• [Effects of atorvastatin in multiple sclerosis].

  Koh CS. Koh CS. Nihon Rinsho. 2003 Aug;61(8):1455-60. Nihon Rinsho. 2003. PMID: 12962038 Review. Japanese.
• Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.

  Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F. Aktas O, et al. J Exp Med. 2003 Mar 17;197(6):725-33. doi: 10.1084/jem.20021425. Epub 2003 Mar 10. J Exp Med. 2003. PMID: 12629065 Free PMC article.
• Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

  Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Weber MS, et al. J Neuroinflammation. 2014 Feb 6;11:29. doi: 10.1186/1742-2094-11-29. J Neuroinflammation. 2014. PMID: 24498870 Free PMC article.
• Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.

  Neuhaus O, Hartung HP. Neuhaus O, et al. Expert Rev Neurother. 2007 May;7(5):547-56. doi: 10.1586/14737175.7.5.547. Expert Rev Neurother. 2007. PMID: 17492904 Review.